Protara Therapeutics (TARA)
Develops investigational therapies for cancer, lymphatic malformations, and patients receiving parenteral support.
$3.55
vs last close−0.14 (−3.67%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | ≈ 78.24% | 46.24M shares | |
|---|---|---|---|
| 123 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 1.86% | 1.10M shares | |
| 7 holders · as of Jul 1, 2026 | |||
| Strategic holders | 8.81% | 5.21M shares | |
| 1 holder · as of May 15, 2026 | |||
| Other | ≈ 11.09% | 6.55M shares | |
| remainder | |||
59.10M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
13F, as of Jun 30, 2026
123 holders · 46.24M shares · 28 new positions · 80 increased · 27 reduced · 20 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Jupiter Topco LLC | 4.70M | 7.95% | +4.70Mnew | Aug 14, 2026 |
| BlackRock, Inc. | 3.66M | 6.20% | +268.5K | Aug 7, 2026 |
| Millennium Management LLC | 3.10M | 5.25% | +270.0K | Aug 14, 2026 |
| Velan Capital Investment Management LP | 2.84M | 4.81% | +10.0K | Aug 14, 2026 |
| Vanguard Capital Management LLC | 2.30M | 3.89% | +181.1K | Aug 13, 2026 |
| Blackstone Inc. | 2.27M | 3.83% | 0 | Aug 14, 2026 |
| Orbimed Advisors LLC | 2.22M | 3.76% | +2.22Mnew | Aug 14, 2026 |
| Sio Capital Management, LLC | 1.92M | 3.25% | −48.0K | Aug 14, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Janus Henderson Group PLC | 9.60% | 5.21M | 13G | May 15, 2026 |
| Woodline Partners LP | 7.40% | 1.58M | 13G | Nov 14, 2024 |
| BlackRock, Inc. | 6.30% | 3.39M | 13G | Apr 27, 2026 |
| Velan Capital Management LLCincl. Velan Capital Holdings LLC, Velan Horizon Fund LP +5 more | 5.90% | 2.06M | 13G | Dec 17, 2024 |
| Millennium Management LLC | 5.10% | 2.76M | 13G | Mar 2, 2026 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Jun 29, 2026 | Jesse Sheffermandirector, officer: CEO and President | Sale | 215,687 | $4.09 | 721,832 |
| Apr 8, 2026 | Jacqueline Zummoofficer: Chief R&D Officer | Sale | 1,134 | $5.40 | 94,827 |
| Apr 1, 2026 | Jacqueline Zummoofficer: Chief R&D Officer | Sale | 22,598 | $5.26 | 95,961 |
House and Senate disclosures
Not reported.